Biotech startup Airna raises $60M for RNA editing medicines
Bio Pharma Dive
JULY 31, 2024
Launched last September, the company is working on a treatment for alpha-1 antitrypsin deficiency, which it said could enter the clinic in 2025.
Wed.Jul 31, 2024
293 
One Diet Choice While Pregnant May Protect Your Child’s Heart For Life
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 31, 2024
The food consumed by a pregnant mother just got a little bit more important. According to a new study on pregnant mice, a diet rich in fiber improves the long-term heart health of developing offspring, significantly lowering their risk of cardiovascular disease later in life.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GSK cuts vaccine forecasts, while predicting faster overall growth
Bio Pharma Dive
JULY 31, 2024
Several factors are slowing U.S. sales of Shingrix, the shingles vaccine that's become one of the British pharma's top sellers.
Pfizer’s Q2 2024 net income attributable to shareholders down 98%
Pharmaceutical Technology
JULY 31, 2024
Pfizer has posted a 98% decrease in net income attributable to shareholders of $41m for Q2 2024, compared to $2.3bn in Q2 2023.
How to Turn “Check-the-Box” Compliance Trainings Into Real Learning
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance trainings aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, relevant, and maybe even enjoyable! Join expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training programs. You’ll discover creative strategies to turn traditionally dry topics into meaningful learning experiences that resonate and drive real change.
Merck shares slide as Gardasil sales drop in China
Bio Pharma Dive
JULY 31, 2024
The unexpected disclosure in Merck’s second quarter earnings prompted an investor sell-off that some analysts say may be overblown.
MSD reports net income of $5.4bn in Q2 2024
Pharmaceutical Technology
JULY 31, 2024
MSD has reported a net income on a GAAP basis of $5.4bn for Q2 2024 compared to the net loss of $5.9bn in the same quarter of 2023.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Magazine: Left in limbo: when pharma halts rare disease research
Pharmaceutical Technology
JULY 31, 2024
Gene therapy research is expensive. Biotechs invest millions of dollars in early research to develop therapies for conditions that might be rare. But when funds are limited and the market potential is dim, such programs are often abandoned by companies, leaving patients and investigators in a bind.
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
Bio Pharma Dive
JULY 31, 2024
Elsewhere, Fibrogen plans to lay off three-quarters of its U.S. staff, while gene editing specialist Intellia is now cleared to start a U.K. study focused on AAT deficiency.
FDA approves J&J’s multiple myeloma therapy
Pharmaceutical Technology
JULY 31, 2024
The US FDA has granted approval for Johnson & Johnson’s (J&J) DARZALEX FASPRO for treating newly diagnosed multiple myeloma (NDMM).
EPSRC launches two new hubs to transform early disease diagnosis in the UK
Pharma Times
JULY 31, 2024
Quantum-based technologies will explore infectious diseases, cancer and dementia
Clinical Research White Paper – Enhancing Transparency & Efficiency Throughout the Trial Lifecycle
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Vertex’s blockbuster-in-waiting painkiller suzetrigine set for FDA review next year
Pharmaceutical Technology
JULY 31, 2024
The FDA has set a PDUFA target action date of 30 January 2025 for Vertex’s acute pain treatment therapy that is a non-opioid alternative.
July 31, 2024: Gene Editing Therapies and Population Health, in This Week’s PCT Grand Rounds
Rethinking Clinical Trials
JULY 31, 2024
Dr. Adrian Hernandez In this Friday’s PCT Grand Rounds, Adrian Hernandez of Duke University will present “Precision Health to Population Health: Opportunities and Challenges for Gene Editing Therapies.” The Grand Rounds session will be held on Friday, August 2, 2024, at 1:00 pm eastern. Hernandez is a professor of medicine and vice dean in the Duke University School of Medicine and the executive director of the Duke Clinical Research Institute.
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
Pharmaceutical Technology
JULY 31, 2024
FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.
Apollo and Oxford University enter drug discovery and development collaboration
Pharma Times
JULY 31, 2024
The latest collaboration marks Apollo’s sixth agreement with a research institution
Can Your Organization Spot a Conflict Before It’s a Crisis?
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023
Pharmaceutical Technology
JULY 31, 2024
The biopharmaceutical industry experienced varied revenue shifts in 2023, with significant success for companies with obesity drugs.
Frontiers Health 2024: Connecting changemakers, cultivating health system change
pharmaphorum
JULY 31, 2024
Frontiers Health 2024 is a platform connecting innovators and changemakers in the life sciences industry to cultivate positive changes in health systems. Discover the latest trends and insights in healthcare innovation.
Imunon’s shares soar after IL-12 therapy success in Phase II trial
Pharmaceutical Technology
JULY 31, 2024
In the intent-to-treat cohort, IMNN-001 plus chemotherapy offered a median 11.1-month increase in overall survival versus chemotherapy alone.
Vertex eyes FDA decision on non-opioid pain drug in January
pharmaphorum
JULY 31, 2024
Vertex has filed for FDA approval of its non-opioid pain drug suzetrigine, starting the clock ticking on a review that should be completed early next year
White Paper - A Roadmap to AI Data Readiness in R&D Labs
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Novo faces growth challenges despite GLP-1 receptor agonist obesity boom
Pharmaceutical Technology
JULY 31, 2024
The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.
Patients resist Novo Nordisk plan to stop making Levemir
pharmaphorum
JULY 31, 2024
Patient advocacy group APIC has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir
Leveragen and Moderna link to advance therapeutics
Pharmaceutical Technology
JULY 31, 2024
Leveragen and Moderna have entered a research, option and licence agreement to advance the development of various therapeutics.
How biometrics applications are contributing to clinical trial diversity
pharmaphorum
JULY 31, 2024
Ensuring equitable access to medications remains a fundamental commitment for many pharmaceutical companies to their customers, patients, and stakeholders. However, there has been a discernible shift recently in the timing of access discussions.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA drug application costs set to rise to $4.3m from October
Pharmaceutical Technology
JULY 31, 2024
The US Food and Drug Administration application fees have increased by around $300,000 from 2024 and by $2 million compared to a decade ago.
After EU setback, Eisai/Biogen build case for Leqembi
pharmaphorum
JULY 31, 2024
Eisai, Biogen report data showing benefit of Alzheimer's disease therapy Leqembi builds with time, with no increase in safety risk
Amgen in internet of things: theme innovation strategy
Pharmaceutical Technology
JULY 31, 2024
How many patents did Amgen submit related to internet of things last quarter, and how many were granted? Discover the latest information here.
Bayer lops off 70 more employees at New Jersey headquarters
Fierce Pharma
JULY 31, 2024
Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more workers at the site. | Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more at the site, according to a state Worker Adjustment and Retraining Notification.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Leqselvi Can Achieve Nearly 90% Scalp Hair Coverage in Severe Alopecia Areata Patients
XTalks
JULY 31, 2024
The US Food and Drug Administration (FDA) has just approved Leqselvi (deuruxolitinib), a new oral medication by Sun Pharmaceutical Industries Limited, offering significant hope for those suffering from severe alopecia areata, a condition causing sudden hair loss. This approval marks a significant milestone, bringing new possibilities to the estimated 300,000 people in the US who deal with severe forms of this autoimmune disease.
13 Proven Tactics to Outmaneuver Generic Drug Rivals
Drug Patent Watch
JULY 31, 2024
By implementing these strategies, you can can enhance your competitiveness in the market while contributing to increased access to affordable […] Source
Pharma Pulse 7/31/24: In the Specialty Drug Spend — Biologics Rule, Big Pharma Rallies and Moves Past Obesity & more
Pharmaceutical Commerce
JULY 31, 2024
The latest news for pharma industry insiders.
Best Practices for Drug Patent Portfolio Management: Maximizing Value in Pharmaceutical Innovation
Drug Patent Watch
JULY 31, 2024
In the high-stakes world of pharmaceutical development, effective patent portfolio management can mean the difference between blockbuster success and costly […] Source
Let's personalize your content